The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Tumor antigens and vaccines in colorectal cancer
Wu, Z., Yang, M., & Cao, Y. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100144 · Cited by 8
Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3
Tate, T., Matsumoto, S., Nemoto, K., Leisegang, M., Nagayama, S., Obama, K., Nakamura, Y., & Kiyotani, K. (2023) · Cancers · doi:10.3390/cancers15041031 · Cited by 8
White, B. S., Sindiri, S., Hill, V. K., Gasmi, B., Nah, S., Gartner, J. J., Prickett, T. D., Li, Y., Gurusamy, D., Robbins, P. F., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006303 · Cited by 8
Self-citationMattila, J., Sormunen, S., Heikkilä, N., Mattila, I. P., Saramäki, J., & Arstila, T. P. (2023) · Cancer Medicine · doi:10.1002/cam4.6002 · Cited by 8
Evolving Tumor Characteristics and Smart Nanodrugs for Tumor Immunotherapy
Sun, W., Xie, S., Liu, S., Hu, X., & Xing, D. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s453265 · Cited by 8
Discovery platforms for RNA therapeutics
Ciucci, G., Braga, L., & Zacchigna, S. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16424 · Cited by 8
Yoon, J., Fagan, E., Jeong, M., & Park, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c03518 · Cited by 8
Kemps, P. G., Zondag, T. C. E., Steenwijk, E. C., Andriessen, Q., Borst, J., Vloemans, S. A., Roelen, D. L., Voortman, L. M., Verdijk, R. M., van Noesel, C. J. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03045 · Cited by 8
Ferrari, V., Tarke, A., Fields, H. F., Ferrari, L., Conley, T., Ferrari, F., Koşaloğlu‐Yalçın, Z., Sette, A., Peters, B., McCarthy, C., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.10.003 · Cited by 9
Adoptive T-cell Immunotherapy: Perfecting Self-Defenses
Zur-Toledano, R., Adler, G., Shamalov, K., Tal, Y., Ankri, C., & Cohen, C. J. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_9 · Cited by 9
Verkerk, T., Koomen, S. J. I., Fuchs, K. J., Griffioen, M., & Spaapen, R. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119736119 · Cited by 8
Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies
Knochelmann, H. M., Rivera-Reyes, A. M., Wyatt, M. M., Smith, A. S., Chamness, R., Dwyer, C. J., Bobian, M. R., Rivera, G. O. R., Horton, J. D., Lilly, M. B., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1959101 · Cited by 8
Immunotherapy for Treatment of Cancer
Karachi, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81150 · Cited by 8
Li, Y., Liu, S., Hong, C., Ma, Q., Tan, F., Liu, C., Kuśnierczyk, P., Li, C., Shi, L., & Yao, Y. (2019) · Journal of Cancer · doi:10.7150/jca.33566 · Cited by 8
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Aderonke, A. B., Ibrahim, R. B., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184624 · Cited by 8
Advances in TIL therapy: Expanding the horizons beyond melanoma
Wiertsema, P., Tan, Y., Haanen, J. B. A. G., Seijkens, T. T. P., & Jedema, I. (2025) · Med · doi:10.1016/j.medj.2025.100702 · Cited by 7
IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation
Wang, S., Yu, G., Dai, Y., Gan, C., Qiu, S., Zhang, X., Jiang, X., Wei, R., Yang, J., Wu, D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3086 · Cited by 7
Shi, Q., Simon, E. P., Bozkus, C. C., Kaminska, A., Velazquez, L. G., Saxena, M., Zhang, Z., Belk, J. A., Wang, S., Yang, N., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02268-1 · Cited by 7
Lu, Z., Zhu, W., & Liu, X. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152399 · Cited by 9
Sewastianik, T., Roy, C., Gormally, M. V., Montesion, M., Halvey, P. J., Jindal, A., Lam, H., Schoenfeld, A. J., Klebanoff, C. A., Opiteck, G. J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012435 · Cited by 7
Arruda, L. C. M., Karbach, J., Kiselicki, D., Altmannsberger, H., Sinelnikov, E., Gustavus, D., Hoffmeister, H., Atmaca, A., & Jäger, E. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2559784 · Cited by 7
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
Coukos, G., Donia, M., Gastman, B., Goff, S. L., Gros, A., Harari, A., Hernandez, S., Ito, F., Maker, A. V., Mullinax, J. E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013420 · Cited by 7
Alrumaihi, F., Alromaihi, R. A., Kumar, V., & Anwar, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121056 · Cited by 8
Cai, Y. R., Chen, R., Song, M., Wang, L., Huo, Z., Yang, D., Zhang, S., Gao, S., Hwang, S.-J., Bai, L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1722117 · Cited by 7
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7
Song, H., Wang, H., Gong, M., Wu, L., Liu, X., Cao, W., Gao, X., Dou, R., Chen, Q., & Hu, H. (2021) · Cell Biology International · doi:10.1002/cbin.11729 · Cited by 8
Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
Peng, X., Xia, Z., Guo, Y. S., & Li, Y. (2023) · Aging · doi:10.18632/aging.204770 · Cited by 7
Choi, S., Hossain, M., Lee, H., Baek, J., Park, H. S., Lim, C.-L., Han, D., Park, T.-H., Kim, J. H., Gong, G., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03691-9 · Cited by 7
Porter, L. H., Harrison, S., Risbridger, G. P., Lister, N. L., & Taylor, R. A. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106571 · Cited by 7
Utilization of primary tumor samples for cancer neoantigen discovery
Leko, V., Groh, E. M., Levi, S. T., Copeland, A. R., White, B. S., Gasmi, B., Li, Y., Hill, V. K., Gurusamy, D., Levin, N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010993 · Cited by 7
Self-citationOverview of Current Immunotherapies Targeting Mutated KRAS Cancers
Hoo, W. P. Y., Siak, P. Y., & In, L. L. A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190904163524 · Cited by 7
Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
Miljanic, M., Capasso, A., Triplett, T., Eckhardt, S. G., & Aung, K. L. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_1_20 · Cited by 7
Understanding the impact of immune-mediated selection on lung cancer evolution
Rosenthal, R., Swanton, C., & McGranahan, N. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01232-6 · Cited by 7
Terada, K., Kondo, K., Ishigaki, H., Nagashima, A., Satooka, H., Nagano, S., Masuda, K., Kawamura, T., Hirata, T., Ogasawara, K., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.003 · Cited by 7
Wang, S., Zhang, X., Zou, X., Wen, M., Gan, C., Jiang, X., Li, M., Shen, R., Zhu, D., Yao, A., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03335-w · Cited by 7
Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients
Zhu, Y., Meng, M., Hou, Z., Wang, W., Li, L., Guan, A., Wang, R., Tang, W., Yang, F., Zhao, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1122669 · Cited by 7
Gao, S., Wang, J., Zhu, Z., Fang, J., Zhao, Y., Liu, Z., Qin, H., Wei, Y., Xu, H., Dan, X., et al. (2023) · Immunotherapy · doi:10.2217/imt-2021-0339 · Cited by 7
Meyer, M., Parpoulas, C., Barthélémy, T., Becker, J. P., Charoentong, P., Lyu, Y., Börsig, S., Bulbuc, N., Tessmer, C., Weinacht, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294565 · Cited by 7
A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling
Kauke, M. J., Tisdale, A. W., Kelly, R. L., Braun, C. J., Hemann, M. T., & Wittrup, K. D. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0645 · Cited by 8
Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
Rosati, G., Aprile, G., Basile, D., & Avallone, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602596 · Cited by 7
Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
Díaz-Cano, I., Paz-Ares, L. G., & Otano, I. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.003 · Cited by 7
Diffusion-based generation of gene regulatory networks from scRNA-seq data with DigNetPreprint
Wang, C., & Liu, Z. (2024) · Genome Research · doi:10.1101/gr.279551.124 · Cited by 8
Chen, X. T., Leisegang, M., Gavvovidis, I., Pollack, S. M., Lorenz, F. K. M., Schumacher, T. N., Daumke, O., & Blankenstein, T. J. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1524629 · Cited by 6
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma
McClelland, P. H.-T., Nah, S., Gustafson, A. M., Dinerman, A. J., White, B. S., Gasmi, B., White, D. E., Sindiri, S., Gartner, J. J., Prickett, T. D., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02348 · Cited by 6
Self-citationSkok, K., Macciò, U., Martin, S. D., & Bräutigam, K. (2025) · Cancer Medicine · doi:10.1002/cam4.71023 · Cited by 7
Mehr, F. K., Emtiazi, N., & Zolfi, E. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103169 · Cited by 6
Kumar, V., Danodia, A. K., Jadhavar, P. S., Mohanty, S. K., & Samanta, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118555 · Cited by 8
Bright side of the dark genome: antigens for next-gen cancer vaccines
Wang, X., & Fox, B. A. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014075 · Cited by 6
Potential Use of Shared Frameshift Mutations in ‘Off-the-Shelf’ Neoantigen Vaccines
Thol, K., & McGranahan, N. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.002 · Cited by 6
Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
Bhattacharya, S., & Rajpurohit, T. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220128161647 · Cited by 6
Iizuka, A., Akiyama, Y., Sakura, N., Kanematsu, A., Kikuchi, Y., Nagashima, T., Urakami, K., Shimoda, Y., Ohshima, K., Shiomi, A., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.13910 · Cited by 6
Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review)
Silva-Hurtado, T. J., Inocencio, J. F., & Yong, R. L. M. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2757 · Cited by 6
ZHENG, W., Jiang, D., Chen, S., Wu, M., Yan, B., Zhai, J., Shi, Y. E., Xie, B., Xie, X., Hu, K., et al. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.056565 · Cited by 6
Gupta, T., & Murtaza, M. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.02.003 · Cited by 6
Booming cancer immunotherapy fighting tumors
Li, D., & Wang, W. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9208-1 · Cited by 6
Takimoto, R., Kamigaki, T., Gotoda, T., Takahashi, T., Okada, S., Ibe, H., Oguma, E., & Goto, S. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02634-z · Cited by 6
Quintarelli, C., Camera, A., Ciccone, R., Alessi, I., Bufalo, F. D., Carai, A., Baldo, G. D., Mastronuzzi, A., & Angelis, B. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634031 · Cited by 6
Ras Isoforms from Lab Benches to Lives—What Are We Missing and How Far Are We?
Nair, A., Kubatzky, K. F., & Saha, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126508 · Cited by 7
Duhen, T. M., Gough, M. J., Leidner, R. S., & Stanton, S. E. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2022.902160 · Cited by 6
Vaccines Targeting Gliomas: Antigens Matter
Platten, M., & Graßl, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02616 · Cited by 6
Emerging Challenges to Cellular Therapy of Cancer
Lulla, P., & Brenner, M. K. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000637 · Cited by 6
Immisch, L., Papafotiou, G., Delgado, N. G., Scheuplein, V., Paschen, A., Blankenstein, T. J. F., & Willimsky, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1119498 · Cited by 6
Sinha, D., Smith, C., & Khanna, R. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.005 · Cited by 6
Research advance in tumor specific antigens: a narrative review
Takahashi, Y., Demachi‐Okamura, A., Oya, Y., Nakada, T., Sakakura, N., Kuroda, H., & Matsushita, H. (2021) · AME Medical Journal · doi:10.21037/amj-20-121 · Cited by 6
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
Smole, A. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0049 · Cited by 8
Yuan, C., Huang, J., Li, H., Zhai, R., Zhai, J., Fang, X., & Wu, Y. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2023.1102545 · Cited by 6
Current status of immunotherapy in gastrointestinal malignancies
Lorenzen, S., Lordick, F., Loosen, S. H., Tacke, F., Trautwein, C., Roderburg, C., Ettrich, T. J., Perkhofer, L., Reinacher‐Schick, A., & Stein, A. (2020) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1071-8322 · Cited by 6
Zhang, H., Dong, W., Zhao, H., Zeng, Z., Zhang, F., Hu, Y., Li, Q., Chen, J., Meng, E., & Xiao, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3825 · Cited by 6
Baek, J., Choi, G., Lee, G., Lee, H., Gong, G., Park, H. S., Kim, J. Y., Kim, J. Y., & Lee, H. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-85892-5 · Cited by 5
Immuno-oncology recapitulates ontogeny: Modern cell and gene therapy for cancer
Carleton, N. M., Rosen, A. B. I., Das, J., & Lotze, M. T. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.042 · Cited by 5
Systematic identification of lincRNA-derived immunogenic peptides in melanoma
Dupré, E., Guiho, A., Beauvais, T., Labous, L., Cardon, T., Bertolotto, C., Khammari, A., Quereux, G., Salzet, M., Labarrière, N., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2538684 · Cited by 5
Zheng, X., Zhao, Y., & Liu, Z. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.07.001 · Cited by 5
Advances in treatment strategies for low-grade serous ovarian cancer
Musacchio, L., Lorusso, D., Sabetta, G., Giustozzi, A., Giudice, E., Cannizzaro, M. C., Perri, M. T., Fagotti, A., & Salutari, V. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103019 · Cited by 5
Mechanisms and current advances in treating KRAS-mutated lung cancer
Chao, C. H.-Y., & Di, Y. P. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.08.001 · Cited by 6
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update
Lu, J., Yu, J., Xu, T., Li, Y., Chen, S., Zhou, Q., & Wang, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.126 · Cited by 5
Advances in the development of personalized neoantigen therapies
Brightman, S. E., & Butterfield, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241234 · Cited by 5
Insights into RAS-driven melanoma and its therapeutic implications
Chatziioannou, E., Lallas, K., Sinnberg, T. W., Niessner, H., Stratigos, A., Flatz, L., & Amaral, T. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103090 · Cited by 5
Pan, J., Chen, S., Jin, L., Chen, K., Ye, Z., & Li, B. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189544 · Cited by 6
Advances in cell therapy for solid tumours: European perspective and future directions
Moreno, V., Thistlethwaite, F. C., Yarza, R., Tak, W. S., Lim, K. H. J., & Haanen, J. B. A. G. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101590 · Cited by 5
Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy
Plewa, N., Poncette, L., & Blankenstein, T. J. F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006001 · Cited by 5
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 5
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies
Vanclooster, P., Seghers, S., & Prenen, H. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001042 · Cited by 5
Research advances on TIL therapy for colorectal cancer
Jiang, J., Shu, W., & Yao, Q. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03530-4 · Cited by 5
More T cell receptors to the RAScue in cancer?
Tran, E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci184782 · Cited by 5
Self-citationPeptide-MHC I regulatory mechanisms and intervention strategies in anti-tumor T cell immunity
Zhang, Z., Shen, Y. J., Lin, Y.-S., Yang, B., Cao, J., Li, J., & Zhao, W. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01574-y · Cited by 5
Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions
Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189382 · Cited by 6
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer
Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S. D., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 6
Tumor immunotherapy: past, present, and future
Huang, Y., Ge, H., Zhang, Z., Liu, X., Zhong, K., Tong, A., Li, G., & Zhou, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002919 · Cited by 6
Shen, M., Hao, Y., Han, X., Wang, B., Luo, L., Chen, T., Chen, S., Zou, L., Huang, J., Wang, W., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011863 · Cited by 5
Meade, E., & Garvey, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178307 · Cited by 5
Sharon, S., Baird, J. R., Bambina, S., Kramer, G. F., Blair, T. C., Jensen, S. M., Leidner, R. S., Bell, R. B., Casap, N., Crittenden, M. R., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27982 · Cited by 5
Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy
Baleeiro, R. B., Chard, L. S., Liu, P., Lu, S., Lone, Y. C., Lemoine, N. R., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.902709 · Cited by 6
Cellular Therapies: Yesterday, Today, and Tomorrow
Mayani, H. (2023) · Stem Cells and Development · doi:10.1089/scd.2022.0294 · Cited by 5
In silico design of high-affinity antigenic peptides for HLA-B44
Feng, M., Chan, C., Zhong, Q., & Zhou, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131356 · Cited by 5
Palomero, J., Galvao, V., Creus, I., Lostes, J., Aylagas, M., Marín-Bayo, A., Rotxés, M., Sanz, M. Á., Lozano-Rabella, M., García-Garijo, A., et al. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.101030 · Cited by 5
Self-citationA therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors
Bei, Y., Huang, Y., Wu, N., Li, Y., Xu, R., Liu, B., & Li, R. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00184-1 · Cited by 5
Fall of the mutants: T cells targeting BCR-ABL
Lulla, P., & Heslop, H. E. (2017) · Blood · doi:10.1182/blood-2016-12-757336 · Cited by 5
Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy
Hinrichs, C. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120386 · Cited by 5
Chasing neoantigens; invite naïve T cells to the party
Bollineni, R. C., Tran, T. T., Lund‐Johansen, F., & Olweus, J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102172 · Cited by 5
Role of Surgery in Combination with Immunotherapy
Klemen, N. D., Shindorf, M. L., & Sherry, R. M. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.011 · Cited by 5
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
